SSII Reports Record Q2 Revenue Up 39.4%

By Greg Peters • Thursday, August 13 13:00 • Permanent Link

SS Innovations International posted a record second quarter as revenue climbed 39.4% to $13.9 million from $10.0 million a year earlier, driven mainly by higher system sales and a sharp increase in surgical activity.

System sales rose 40.8% to $12.36 million from $8.78 million in the prior-year quarter, accounting for most of the top-line gain. Instrument sales increased 13.4% to $1.14 million from $1.01 million, while warranty sales more than doubled to $419,002 from $193,359. Lease income slipped 10.4% to $16,196 from $18,078.

Gross profit increased 20.0% to $7.1 million from $5.9 million, even as gross margin narrowed to 50.9% from 59.1% in the second quarter of 2025.

The company reported a net loss of $2.7 million, compared with a net loss of $0.3 million a year earlier. Diluted loss per share was $(0.01), versus $(0.00) in the prior-year quarter.

Installations of the SSI Mantra surgical robotic system rose to 30 from 23, up 30.4%. Surgical volume more than doubled, with SSI Mantra surgeries reaching 2,528 from 1,042, an increase of 142.6%. The cumulative installed base reached 224 systems at June 30, 2026, up from 105 a year earlier, and cumulative surgeries climbed to 12,272 from 4,657.

For the first half of 2026, revenue increased 65.6% to $25.0 million from $15.1 million. System sales rose 65.1% to $21.94 million, instrument sales advanced 54.5% to $2.29 million, and warranty sales jumped 145.9% to $776,688. Lease income declined 8.8% to $33,278.

Gross profit for the first six months rose 77.5% to $12.4 million from $7.0 million, while gross margin expanded to 49.6% from 46.3%.

The first-half net loss widened slightly to $6.2 million from $5.9 million. Diluted loss per share held at $(0.03).

First-half installations increased to 56 from 38, up 47.4%, and surgeries rose to 4,387 from 1,861, a gain of 135.7%.

As of June 30, 2026, SS Innovations had $13.6 million in cash and cash equivalents and no long-term debt. Today the company's shares have moved 2.98% to a price of $3.80. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.